降糖药物对2型糖尿病肝脏事件预防及干预比较:HEPATIC-T2DM网络荟萃分析
该研究基于46项观察性研究(N=7,124,845)进行贝叶斯网络荟萃分析,比较不同降糖药物类别与2型糖尿病患者主要不良肝脏结局的关联。结果显示肝脏特异性风险降低因药物类别而异:噻唑烷二酮类与肝细胞癌风险关联最低,GLP-1受体激动剂与失代偿 composite 风险关联最低,SGLT2抑制剂与肝硬化风险关联最低。所有纳入研究均为观察性,无法推断因果关系,需随机试验验证。
要点
- 噻唑烷二酮类与肝细胞癌风险关联最低,显著低于DPP-4抑制剂、GLP-1RAs、胰岛素和磺脲类。
- GLP-1RAs与失代偿复合结局风险关联最低(HR 0.16-0.91,均显著)。
- SGLT2抑制剂与肝硬化风险关联最低,GLP-1RAs与静脉曲张出血和肝性脑病关联最低。
核心结论
- 肝脏特异性风险降低在不同降糖药物类别间并不一致。
- 需随机试验确定这些关联是否反映真实药物效应。
研究设计与样本
- 研究为三水平贝叶斯网络荟萃分析,纳入46项观察性研究,总样本量N=7,124,845。
- 检索PubMed、EMBASE和Cochrane Central Register of Controlled Trials,时间从1946年12月至2025年8月23日。
主要发现
- 噻唑烷二酮类与肝细胞癌发生率关联最低,显著低于DPP-4抑制剂(HR 0.50)、GLP-1RAs(HR 0.72)、胰岛素(HR 0.20)和磺脲类(HR 0.69)。
- 对于失代偿复合结局,GLP-1RAs与最低风险关联,相比所有其他类别HR为0.16-0.91(均显著)。
- SGLT2抑制剂与肝硬化风险关联最低(对比DPP-4抑制剂HR 0.66;对比GLP-1RAs HR 0.66)。
- GLP-1RAs与静脉曲张出血和肝性脑病风险关联最低,SGLT2抑制剂与肝脏相关死亡率关联最低。
关键数值与推荐
- 噻唑烷二酮类 vs DPP-4抑制剂:肝细胞癌HR 0.50;vs GLP-1RAs:HR 0.72;vs 胰岛素:HR 0.20;vs 磺脲类:HR 0.69。
- GLP-1RAs vs 其他类别:失代偿复合结局HR 0.16-0.91(均显著)。
- SGLT2抑制剂 vs DPP-4抑制剂:肝硬化HR 0.66;vs GLP-1RAs:HR 0.66。
临床怎么用
- 对于T2DM患者,选择降糖药物时可考虑其对肝脏结局的潜在差异化关联。
- 噻唑烷二酮类、GLP-1RAs和SGLT2抑制剂在不同肝脏结局上显示最低风险关联,但需结合患者个体情况。
- 观察性证据提示肝脏获益非类效应,临床决策应综合评估肝病风险。
局限性
- 所有纳入研究均为观察性,无法进行因果推断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Type 2 diabetes mellitus (T2DM) amplifies liver disease burden, yet the comparative hepatic effects of glucose-lowering drugs remain poorly defined. PURPOSE: To compare associations between glucose-lowering drug classes and major adverse liver outcomes (MALOs) in adults with T2DM. DATA SOURCES: PubMed, EMBASE, and Cochrane Central Register of Controlled Trials were searched from December 1946 through 23 August 2025. STUDY SELECTION: Studies enrolling adults with T2DM that evaluated associations between glucose-lowering drug classes with regard to MALOs were included. DATA EXTRACTION: Data were extracted on study characteristics, drug exposures, and MALOs. DATA SYNTHESIS: A three-level Bayesian network meta-analysis with study- and database-level random effects was performed. Outcomes are reported as hazard ratios (HRs) and ranked using the surface under the cumulative ranking curve. Forty-six observational studies (N = 7,124,845) were included. Thiazolidinediones were least associated with hepatocellular carcinoma incidence and significantly lower than dipeptidyl peptidase 4 (DPP-4) inhibitors (HR 0.50), glucagon-like peptide 1 receptor agonists (GLP-1RAs) (HR 0.72), insulin (HR 0.20), and sulfonylureas (HR 0.69). For decompensation (composite), GLP-1RAs were associated with the lowest hazard compared with all other classes (HRs 0.16-0.91; all significant). Sodium-glucose cotransporter 2 (SGLT2) inhibitors were least associated with cirrhosis (HR 0.66 vs. DPP-4 inhibitors; HR 0.66 vs. GLP-1RAs). GLP-1RAs were least associated with variceal bleeding and hepatic encephalopathy, whereas SGLT2 inhibitors were least associated with liver-related mortality. LIMITATIONS: All included studies were observational, precluding causal inference. CONCLUSIONS: Liver-specific risk reduction is not uniform across antihyperglycemic drug classes. Randomized trials are needed to determine whether these associations reflect true drug effects.
引用
- Passos PRC, Motta R, Oliveira Costa Filho V, et al. Hepatic Events Prevention by Antihyperglycemic Therapies and Intervention Comparisons in Type 2 Diabetes: The HEPATIC-T2DM Network Meta-analysis. Diabetes Care. 2026. PMID: 41973508. doi:10.2337/dc26-0336
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。